                         SEQUENCE LISTING

<110>  BioNTech RNA Pharmaceuticals GmbH
 
<120>  DOSE DETERMINATION FOR IMMUNOTHERAPEUTIC AGENTS

<130>  674-171 PCT2

<140>  
<141>  

<150>  PCT/EP2016/075647
<151>  2016-10-25

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Linker sequence


<220>
<221>  REPEAT
<222>  (1)..(3)
<223>  Portion of sequence repeated a times, wherein a is independently 
       a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
       13, 14, 15, 16, 17, 18, 19, or 20

<220>
<221>  MISC_FEATURE
<222>  (1)..(15)
<223>  a + b + c + d + e are different from 0 and preferably are 2 or 
       more, 3 or more, 4 or more or 5 or more

<220>
<221>  REPEAT
<222>  (4)..(6)
<223>  Portion of sequence repeated b times, wherein b is independently 
       a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
       13, 14, 15, 16, 17, 18, 19, or 20

<220>
<221>  REPEAT
<222>  (7)..(9)
<223>  Portion of sequence repeated c times, wherein c is independently 
       a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
       13, 14, 15, 16, 17, 18, 19, or 20

<220>
<221>  REPEAT
<222>  (10)..(12)
<223>  Portion of sequence repeated d times, wherein d is independently 
       a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
       13, 14, 15, 16, 17, 18, 19, or 20

<220>
<221>  REPEAT
<222>  (13)..(15)
<223>  Portion of sequence repeated e times, wherein e is independently 
       a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
       13, 14, 15, 16, 17, 18, 19, or 20

<400>  1

Gly Gly Ser Gly Ser Ser Gly Gly Gly Ser Ser Gly Gly Ser Gly 
1               5                   10                  15  


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  linker sequence

<400>  2

Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   


